News
CFRX
3.070
-8.08%
-0.270
ContraFect Highlights Presentation Of Data On Exebacase At ASM Microbe Conference
YONKERS, N.Y., June 14, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),
Benzinga · 06/14 11:37
Presentations at ASM Microbe Conference Demonstrate Potential of ContraFect’s Direct Lytic Agents (DLAs) to Address MRSA Infections
YONKERS, N.Y., June 14, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical...
GlobeNewswire · 06/14 11:30
70 Stocks Moving In Monday's Mid-Day Session
 Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric low-grade glioma showed an overall response rate of 64%.
Benzinga · 06/13 16:10
Day One Biopharmaceuticals leads healthcare gainers; ContraFect, SciSparc among losers
Gainers: Day One Biopharmaceuticals (DAWN) +111%. Ekso Bionics Holdings (EKSO) +22%. OptiNose (OPTN) +19%. Tivic Health Systems (TIVC) +10%. Belite Bio (BLTE) +7%. Losers: ContraFect (CFRX) -23%. Reviva Pharmaceuticals Holdings (RVPH) -20%.
Seekingalpha · 06/13 14:05
WBB Securities Upgrades ContraFect to Strong Buy from Buy, Sets $7 Price Target
MT Newswires · 06/08 10:00
ContraFect To Present Data Demonstrating The Potential Of Its Direct Lytic Agents To Combat MRSA At ASM Microbe 2022
ContraFect Corporation (NASDAQ:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities
Benzinga · 06/06 11:36
ContraFect to Present Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Combat MRSA at ASM Microbe 2022
YONKERS, N.Y., June 06, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical...
GlobeNewswire · 06/06 11:30
CFRX: Results from Interim Futility Analysis in July 2022…
By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT
Benzinga · 05/26 15:20
Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman
Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than150 business development transactions Former Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals Former...
GlobeNewswire · 05/23 12:00
ContraFect Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
YONKERS, N.Y., May 20, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) (ContraFect), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as...
GlobeNewswire · 05/20 12:30
Contrafect GAAP EPS of -$0.51
Contrafect press release (NASDAQ:CFRX): Q1 GAAP EPS of -$0.51. Cash and cash equivalents of $9.6M
Seekingalpha · 05/16 12:45
ContraFect: Q1 Earnings Insights
  ContraFect (NASDAQ:CFRX) reported its Q1 earnings results on Monday, May 16, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
Benzinga · 05/16 12:29
BRIEF-ContraFect Reports Q1 Loss Per Share $0.51
reuters.com · 05/16 12:29
ContraFect Reports First Quarter 2022 Financial Results and Provides Business Update
Phase 3 DISRUPT study achieves enrollment of MRSA patients necessary for DSMB to conduct interim futility analysisYONKERS, N.Y., May 16, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on ...
GlobeNewswire · 05/16 11:30
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 05/09 12:18
ContraFect Data Presentations at the 32nd Annual ECCMID Meeting Highlight the Potential of Engineered Lysin CF-370 to Improve Clinical Outcomes and Suppress Antimicrobial Resistance Compared to Antibiotics Alone
Oral Session Demonstrates CF-370’s Potent Activity in a Rabbit Pneumonia Model of an Extensively-Resistant Pseudomonas aeruginosa InfectionYONKERS, N.Y., April 27, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotec...
GlobeNewswire · 04/27 12:00
ContraFect Announces Multiple Presentations Of New Data Demonstrating The Potential Of Its Direct Lytic Agents To Address Antimicrobial Resistance At The 32nd Annual ECCMID Meeting
ContraFect Corporation (NASDAQ:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities
Benzinga · 04/18 11:33
ContraFect Announces Multiple Presentations of New Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Address Antimicrobial Resistance at the 32nd Annual ECCMID Meeting
YONKERS, N.Y., April 18, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medica...
GlobeNewswire · 04/18 11:30
CFRX: Futility Analysis for DISRUPT Trial in 1H22…
By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update Update on Phase 3 DISRUPT Trial ContraFect, Corp. (NASDAQ:CFRX) is currently conducting the Phase 3 DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial) trial of ...
Zacks Small Cap Research · 04/04 11:15
Contrafect GAAP EPS of -$0.11 beats by $0.19
Contrafect press release (NASDAQ:CFRX): Q4 GAAP EPS of -$0.11 beats by $0.19. As of December 31, 2021, cash, cash equivalents and marketable securities of $54.3M.
Seekingalpha · 03/24 13:04
More
Webull provides a variety of real-time CFRX stock news. You can receive the latest news about Contrafect Corp through multiple platforms. This information may help you make smarter investment decisions.
About CFRX
ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infection. Its lead DLA candidate includes exebacase, which is an investigational novel lysin that targets Staphylococcus aureus (Staph aureus), including methicillin-resistant (MRSA) strains, which causes serious infections such as bacteremia, pneumonia, and osteomyelitis. Its lysin product candidate, CF-301 is developed for the treatment of Staph aureus bacteremia, including endocarditis, caused by methicillin-resistant Staph aureus and susceptible Staph aureus strains. The Company is conducting Phase II clinical study of exebacase for the treatment of Staph aureus bacteremia, including right-sided endocarditis, caused by MRSA or MSSA.